中国第三款 CanSino 腺病毒单针疫苗。第三期数据(2月8日):总效力 74.8%, 没血栓。已经成为多个国家疫苗护照

那倒没有,保守党可能这么说。看了报纸,很多呼吁用梦换麦克。



加拿大做交易的最佳时机是川普公开说可以用孟晚舟做交易的时候。

但是孟晚舟当时在走法律程序。
土豆和司法部长不敢做决定。
本质上说,是因为体制僵化。
 
加拿大做交易的最佳时机是川普公开说可以用孟晚舟做交易的时候。

但是孟晚舟当时在走法律程序。
土豆和司法部长不敢做决定。
本质上说,是因为体制僵化。
美国不松口,加拿大不敢动。找个不能政治干预的借口。美国如果松口,加拿大就可以以证据不足放人了
 
中国在墨西哥建厂生产康熙诺,诚心气加拿大吧?

不得不说,抓孟晚舟的代价太大了。

Screenshot_20210303_055520.jpg
 
最后编辑:
加拿大应该引进强生疫苗的生产线。打疫苗以后是个长期的事,不能总去买。看在抓孟晚舟,国会宣布新疆灭绝的情分上,美国这点恩惠应该给吧。
 
加拿大应该引进强生疫苗的生产线。打疫苗以后是个长期的事,不能总去买。看在抓孟晚舟,国会宣布新疆灭绝的情分上,美国这点恩惠应该给吧。
加拿大是想建厂生产,可是几家疫苗考察后认为不符合条件。现在却报道说医院要造疫苗,怎么感觉像愚人节消息似的。
 
加拿大应该引进强生疫苗的生产线。打疫苗以后是个长期的事,不能总去买。看在抓孟晚舟,国会宣布新疆灭绝的情分上,美国这点恩惠应该给吧。



mmexport1614776792674.jpg
 
加拿大是想建厂生产,可是几家疫苗考察后认为不符合条件。现在却报道说医院要造疫苗,怎么感觉像愚人节消息似的。



我不相信墨西哥的条件比加拿大的条件好,但是有中国帮助,啥都能建成。
 
我不相信墨西哥的条件比加拿大的条件好,但是有中国帮助,啥都能建成。
加拿大都能自力更生修建轻轨,还能造飞机,印度墨西哥巴西阿联酋都能制造疫苗,加拿大应当也可以。不过工厂通不过,医院造疫苗,听起来有点悬。

不像中国的医院,这边医药是分家的,很多药需要出医院到药店买。

医院连药都不卖,还能造?
 
最后编辑:
小土豆是个好心人,但是政治魄力可比老土豆差远了。在川普下台前几天就应该终止孟晚舟案,换回两个麦克,换来中国疫苗厂。当断不断,必受其乱。现在只能发钱招移民。
 
“packaged in Mexico” 指的是提供有效成分原液,墨西哥完成后面的工序。
大概加拿大也不太希望只是 “packaged in Canada”,谈不拢
我不相信墨西哥的条件比加拿大的条件好,但是有中国帮助,啥都能建成。
 

CanSinoBIO to develop inhaled COVID-19 vaccine, report says​

Trials involving the injectable product had shown 95.47% efficacy in preventing severe COVID-19​

By Alexandria Hein | Fox News

Fox News Flash top headlines are here. Check out what's clicking on Foxnews.com.

A team in China said it’s been given the green light to begin developing an inhaled version of its COVID-19 vaccine, Reuters reported. CanSinoBIO and the Beijing Institute of Biotechnology recently won emergency use approval in Hungary for its injectable vaccine, Convidecia.

The recently issued EUA follows approval already given by Pakistan and Mexico.

"We are pleased to see the authorization by the Hungarian authority for our vaccine, which marks an important step forward in the global fight against the COVID-19 pandemic," Dr. Xuefeng YU, CanSinoBIO’s chairman and chief executive officer, said following Hungary’s EUA. "As CanSinoBIO continues to receive approvals from various governments across different continents, we are focusing on ramping up production capacity to deliver our one-shot vaccines quickly and safely to countries that are in desperate need of mass protection from this pandemic."

NEEDLE-FREE COVID-19 VACCINES IN THE WORKS, WHO SCIENTIST SAYS

The company had not yet published a news release regarding the inhaled version of the vaccine. Previous trials involving the injectable product had shown 95.47% efficacy in preventing severe COVID-19 disease two weeks post-vaccination, according to the company.

The next generation of COVID-19 vaccines currently in development includes needle-free options and those that can be stored at room temperature.

The next generation of COVID-19 vaccines currently in development includes needle-free options and those that can be stored at room temperature. (iStock)

Experts have surmised that the next generation of COVID-19 vaccine may include needle-free options, potentially helping to eliminate hesitancy among groups with sensitivity to needles.

SINOVAC SAYS IT'S COVID-19 VACCINE IS SAFE FOR CHILDREN AS YOUNG AS

According to Bloomberg News, the World Health Organization’s top scientist said as many as six to eight new vaccines may be ready for regulatory review by the end of this year, including ones that don’t require a needle and can be stored at room temperature
Soumya Swaminathan told the news outlet that several experimental candidates use alternative delivery systems, including more single shot jabs and those administered orally, via a nasal spray and even potentially through a skin patch.

"We need to continue to support the research and development of more vaccine candidates, especially as the need for ongoing booster immunization of populations is still not very clear at this point," Swaminathan told Bloomberg News. "So we need to be prepared for that in the future."

 
CHINA / SOCIETY
Clinical trials approved for CanSino’s inhaled COVID-19 vaccine
By
Hu Yuwei
Published: Mar 23, 2021 09:48 PM

CanSino Bio Photo:VCG

CanSino Bio Photo:VCG
China's leading vaccine producer CanSino Biologics obtained the national drug regulator's approval on Monday to start clinical trials of its latest recombinant COVID-19 vaccine (Adenovirus Type 5 Vector) in inhalation form.

The Global Times learned that the vaccine, which was developed in cooperation with the Institute of Military Medicine under the Academy of Military Sciences, is no different in terms of virus species, cell banks, production technology or preparation formula from the company's single-dose Ad5-nCoV COVID-19 vaccine, which is already in use - it just has an additional atomization inhalation device.

The inhaled vaccine can stimulate an immune response in the mucous membranes of a person's respiratory tract. This version is less painful and more accessible, especially for children andvulnerable people, experts said.

The vaccine can be atomized into tiny particles in a device and then inhaled into the respiratory tract and lungs to stimulate mucosal immunity, a Beijing-based immunological expert who prefers to be not identified told the Global Times.

Research has confirmed that respiratory droplets and close contact are still the main transmission routes of the novel coronavirus.

Mucosal immunity acts as the first barrier against the virus and is essential for the prevention of both mild and severe cases, Jiang Chunlai, a professor at Jilin University's School of Life Sciences, told the Global Times.

"We have seen intranasal vaccines against influenza in China. But there have been limited clinical studies on inhaled vaccines. Not all viruses are suitable for inhalation, so further clinical trials are needed," Jiang said.

Clinical trials also need to be conducted to determine the dosage of the nasal spray vaccine, which may be less than the traditional injection, Jiang noted.

CanSinoBIO has tried to improve and accelerate the induced immune level of its COVID-19 vaccine by multiple delivery methods, including intramuscular injection or inhalation.

Researchers from the University of Hong Kong, Xiamen University and Beijing Wantai Biological Pharmacy used a similar mechanism to develop China's first nasal spray vaccine against the novel coronavirus in November 2020.
 

(法新社)消息.
巴基斯坦总统阿尔维本月15日接种中国国药疫苗.在週一(29日),阿尔维在推特中公布确诊消息,指出他在接种首剂中国新冠疫苗后仍验出病毒阳性反应。除了总统阿尔维以外,巴基斯坦总理伊姆兰汗(Imran Khan)本月在注射过第1剂疫苗后,在3月20日也验出病毒阳性反应,目前正在私人住宅中隔离.伊姆兰汗的妻子以及执政党「巴基斯坦正义运动党」的两名高层也确诊阳性。
 
后退
顶部